CHARACTERIZATION OF CD38 EXPRESSION IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) PATIENTS

被引：0

作者：

Buson, E. ^{[1
,2
]}

Calabretto, G. ^{[1
,2
]}

Burattin, A. ^{[4
]}

Gasparini, V. R. ^{[1
,2
]}

Orsi, S. ^{[4
]}

Rampazzo, E. ^{[1
,2
]}

Teramo, A. ^{[1
,2
]}

Trimarco, V. ^{[1
]}

Manni, S. ^{[1
,2
]}

Barila, G. ^{[1
,3
]}

Facco, M. ^{[1
,2
]}

Bortoluzzi, S. ^{[4
]}

Trentin, L. ^{[1
]}

Semenzato, G. ^{[1
,2
]}

Zambello, R. ^{[1
,2
]}

机构：

[1] Padova Univ, Sch Med, Dept Med, Hematol Div, Padua, Italy

[2] Veneto Inst Mol Med VIMM, Padua, Italy

[3] Vicenza Hosp, Hematol Div, Vicenza, Italy

[4] Univ Padua, Dept Mol Med, Padua, Italy

来源：

HAEMATOLOGICA | 2024年 / 109卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P068

引用

页码：91 / 91

页数：1

共 50 条

[21] T-CELL CD38 EXPRESSION IN B-CHRONIC LYMPHOCYTIC LEUKEMIA
Abousamra, Nashwa K.
El-Din, Manal Salah
Azmy, Emad
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1490 - S1490
[22] CAMPATH-1H in the treatment of T-prolymphocytic leukemia (T-PLL).
Cazin, B
Wetterwald, M
Ojeda, M
Mahé, B
Bauters, F
BLOOD, 1999, 94 (10) : 125A - 125A
[23] “T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach”
Carlos A Tirado
Phillip Starshak
Paul Delgado
Nagesh Rao
Experimental Hematology & Oncology, 1 (1)
[24] CDK9 Inhibition with LDC526 Is an Effective Treatment for T-Cell Prolymphocytic Leukemia (T-PLL) in Vitro
Johansson, Patricia
Habenberger, Peter
Klein-Hitpass, Ludger
Duehrsen, Ulrich
Kuppers, Ralf
Schultz-Fademrecht, Carsten
Choidas, Axel
Durig, Jan
BLOOD, 2017, 130
[25] Clinical, Pathological, and Genetic Characteristics of T-Cell Prolymphocytic Leukemia (T-PLL) in a Less Aggressive Course: A Single Institutional Experience
Idrees, Afshan
Horna, Pedro
Sokol, Lubomir
Zhang, Ling
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142
[26] Genomic profiling of T-cell Prolymphocytic Leukemia (T-PLL) identifies novel recurrent mutations in SAMHD1 and PTPRC
Johansson, P.
Klein-Hitpass, L.
Bergmann, A.
Siebert, R.
Scholtysik, R.
Przekopowitz, M.
Seifert, M.
Zenz, T.
Duehrsen, U.
Kueppers, R.
Duerig, J.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 238 - 238
[27] T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach
Tirado, Carlos A.
Starshak, Phillip
Delgado, Paul
Rao, Nagesh
EXPERIMENTAL HEMATOLGY & ONCOLOGY, 2012, 1
[28] T-Cell Prolymphocytic Leukemia (T-PLL) with t(X;14)(q28; q11.2): A Report of 17 Cases
Hu, Zhihong
Xu, Mina
Yuan, Ji
Peker, Deniz
Shao, Lina
Rios, Adan
Medeiros, L. Jeffrey
Hu, Shimin
LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 844 - 844
[29] T-Cell Prolymphocytic Leukemia (T-PLL) with t(X;14)(q28; q11.2): A Report of 17 Cases
Hu, Zhihong
Xu, Mina
Yuan, Ji
Peker, Deniz
Shao, Lina
Rios, Adan
Medeiros, L. Jeffrey
Hu, Shimin
MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 844 - 844
[30] First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)
Alfayez, Mansour
Thakral, Beenu
Jain, Preetesh
Ravandi, Farhad
Ferrajoli, Alessandra
Jain, Nitin
Pemmaraju, Naveen
Wierda, William
Kadia, Tapan
LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 445 - 449

← 1 2 3 4 5 →